NHLBI Research Project Grant, Research Centers Grants, and Other Research Grant Obligations: Fiscal Years 2002?2012

* Includes R01, U01, P01, R03, R15, R21, R29, R33, R37, R41, R42, R43, and R44; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.**Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Research Project Grants, Research Centers Grants, and Other Research Grant Obligations: Fiscal Years 2002?2012

Dollars (Thousands)

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

FY 2008

FY 2009

FY 2010

FY 2011

FY 2012

Research Project Grants*

$1,779,573

$1,920,201

$2,003,769

$2,042,050

$2,011,049

$1,986,692

$1,983,633

$2,039,861

$2,108,524

$2,079,920

$2,092,482

Research Centers Grants

128,161

138,941

140,600

151,495

141,086

141,034

107,393

90,152

72,566

55,931

63,436

Other Research Grants**

98,460

113,172

112,785

116,713

123,802

135,284

125,942

131,001

129,245

152,772

155,661

Total

$2,006,194

$2,172,314

$2,257,154

$2,310,258

$2,275,937

$2,263,010

$2,216,968

$2,261,014

$2,310,335

$2,288,623

$2,311,529

*R01, U01, P01, R03, R15, R21, R29, R33, R37, R41, R42, R43, and R44; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.** Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Cooperative Agreements (U01, U10, U19) Programs

Cooperative Agreements were instituted to support discrete, circumscribed projects in areas of an investigator’s spe­cific interest and competency with substantial programmatic participation by the NHLBI during performance of the activity.

* Formerly known as Targeted Approaches to Weight Control for Young Adults. ** Formerly known as Translating Basic Behavior and Social Science Discoveries Into Interventions to Reduce Obesity.† Formerly known as Clinical Research Consortium To Improve Resuscitation Outcomes.‡ Formerly known as Pharmacomechanical Catheter-Directed Thrombolysis for Acute DVT (ATTRACT) Trial.

Heart and Vascular Diseases Program

ARIC Neurocognitive Study (ARIC-NCS), Initiated in Fiscal Year 2010

The purpose of this study is to determine whether mid-life vascular risk factors and markers of macrovascular and microvascular disease are predictive of dementia, mild cognitive impairment, and cognitive change in a large biracial ARIC cohort.

Obligations

Funding History: Fiscal Year 2012—$783,518 Fiscal Years 2010–2011—$9,156,680 Total Funding to Date—$9,940,198

Current Active Organizations and Grant Numbers

Johns Hopkins University Baltimore, Maryland —HL-096812

University of North Carolina, Chapel Hill Chapel Hill, North Carolina —HL-096814

University of North Carolina, Chapel Hill Chapel Hill, North Carolina —HL-096899

Cardiovascular Cell Therapy Research Network, Initiated in Fiscal Year 2007

The purpose of this trial is to test the inflammatory hypothesis of atherothrombosis by evaluating whether low-dose methotrexate will reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among stable post-myocardial infarction patients with type 2 diabetes or metabolic syndrome—conditions with enhanced pro-inflammatory response.

Obligations

Funding History: Fiscal Year 2012—$9,607,234 Fiscal Year 2011—$1,375,726 Total Funding to Date—$10,982,960

The purpose of this trial is to determine whether renal artery stenting adds value to optimal medical therapy in terms of cardiovascular and renal outcomes in individuals with a history of resistant hypertension and/or chronic kidney disease and stenosis (>60%) of one or both renal arteries.

Obligations

Funding History: Fiscal Year 2012—$2,881,799 Fiscal Years 2004–2011—$28,856,425 Total Funding to Date—$31,738,224

The purpose of this trial is to determine whether percutaneous left atrial catheter ablation is superior to current pharmacologic therapy for eliminating atrial fibrillation.

Obligations

Funding History: Fiscal Year 2012—$3,015,483 Fiscal Years 2009–2011—$9,018,518 Total Funding to Date—$12,034,001

Current Active Organizations and Grant Numbers

Mayo Clinic, College of Medicine Rochester, Minnesota —HL-089645

Mayo Clinic, College of Medicine Rochester, Minnesota —HL-089709

Duke University Durham, North Carolina —HL-089786

Duke University Durham, North Carolina —HL-089907

Center for Cardiovascular Outcomes Research, Initiated in Fiscal Year 2010

The purpose of this program is to conduct cardiovascular outcomes research that focuses on patient- and clinician-relevant outcomes of health care and their determinants. The goal is to move clinical evidence into public policy and clinical practice.

Obligations

Funding History: Fiscal Year 2012—$3,542,609 Fiscal Years 2010–2011—$10,168,525 Total Funding to Date—$13,711,134

Current Active Organizations and Grant Numbers

University of Massachusetts Medical School Worcester, Massachusetts —HL-105268

Yale University New Haven, Connecticut —HL-105270

Duke University Durham, North Carolina —HL-107023

Childhood Obesity Prevention and Treatment Research (COPTR), Initiated in Fiscal Year 2010

The purpose of this study is to optimize physical functioning, increase activity levels, and reduce CVD risk in older individuals with peripheral artery disease. Investigators are determining whether aortoiliac stenting and pharmacotherapy improve maximum walking duration better than supervised rehabilitation, exercise, and pharmacotherapy for those with moderate to severe claudication due to aortoiliac insufficiency.

Obligations

Funding History: Fiscal Year 2012—$542,213 Fiscal Years 2005–2011—$9,018,723 Total Funding to Date—$9,560,936

Current Active Organizations and Grant Numbers

Rhode Island Hospital Providence, Rhode Island —HL-077221

Beth Israel Deaconess Medical Center Boston, Massachusetts —HL-081656

Consortium of Hospitals Advancing Research on Tobacco (CHART), Initiated in Fiscal Year 2010

The purpose of this program is to establish a MAPGen consortium of research centers. The consortium seeks to define common mechanism-associated traits across organ systems and to redefine disease by pathogenetic mechanisms and phenotype individuals based on pathobiology, rather than clinical presentation. This approach will provide the basis for the development of mechanism-based strategies for prevention, diagnosis, and treatment in individual patients.

Obligations

Funding History: Fiscal Year 2012—$4,193,398 Fiscal Year 2011—$4,275,465 Total Funding to Date—$8,468,863

Heart Failure Clinical Research Network, Initiated in Fiscal Year 2006

The purpose of this trial is to determine whether optimal medical therapy plus cardiac catheterization followed by complete revascularization is superior to optimal medical therapy alone as the management strategy for patients with moderate-severe ischemia on stress imaging. Cost-effectiveness will also be assessed.

Obligations

Funding History: Fiscal Year 2012—$17,444,758 Fiscal Year 2011—$6,671,629 Total Funding to Date—$24,116,387

Current Active Organizations and Grant Numbers

Duke University Durham, North Carolina —HL-105462

Emory University Atlanta, Georgia —HL-105561

Duke University Durham, North Carolina —HL-105565

New York University School of Medicine New York, New York —HL-105907

Look AHEAD: Action for Health in Diabetes, Initiated in Fiscal Year 2009

Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine, Initiated in Fiscal Year 2007

Next Generation Genetic Association Studies, Initiated in Fiscal Year 2011

The purpose of this study is to investigate functional aspects of genetic variation in humans by combining cellular reprogramming strategies with molecular profiling or cellular assays, and then integrating the information with existing genotypic and clinical phenotypic data to assess how naturally occurring human genetic variation influences the activities of biological networks in cell-based models of disease. Researchers are seeking to develop the technology needed for high-throughput iPS cell line generation and differentiation and will use the technology to follow up on genomic associations with additional mechanistic information gained from cellular models of disease.

Obligations

Funding History: Fiscal Year 2012—$10,419,521 Fiscal Year 2011—$5,855,804 Total Funding to Date—$16,275,325

Current Active Organizations and Grant Numbers

Stanford University Stanford, California —HL-107388

Stanford University Stanford, California —HL-107393

Scripps Research Institute La Jolla, California —HL-107436

Medical College of Wisconsin Milwaukee, Wisconsin —HL-107437

Massachusetts General Hospital Boston, Massachusetts —HL-107440

University of California, San Diego La Jolla, California —HL-107442

Boston University Medical Campus Boston, Massachusetts —HL-107443

Johns Hopkins University Baltimore, Maryland —HL-107446

NHLBI Cardiac Development Consortium, Initiated in Fiscal Year 2009

The purpose of this study is to elucidate the regulatory networks controlling cardiovascular development. A consortium of multidisciplinary research teams will select key regulatory pathways, identify components of the pathways and targets, and disseminate data to the scientific community. Research results may lead to the development of regenerative therapies and tissue engineering approaches.

Obligations

Funding History: Fiscal Year 2012—$6,978,522 Fiscal Years 2009–2011—$15,276,752 Total Funding to Date—$22,255,274

The purpose of this study is to conduct clinical and translational research on genetic causes of congenital heart disease and genetic contributions to outcomes in individuals with congenital heart disease.

Obligations

Funding History: Fiscal Year 2012—$3,977,556 Fiscal Years 2009–2011—$8,957,755 Total Funding to Date—$12,935,311

The purpose of this Coordinating Center is to provide administrative support for the Cardiovascular Development Consortium and the Pediatric Cardiac Genomics Consortium, monitor multicenter patient recruitment by the Pediatric Cardiac Genomics Consortium, and administer funds to consortium-wide cores.

Obligations

Funding History: Fiscal Year 2012—$7,394,468 Fiscal Years 2009–2010—$10,453,976 Total Funding to Date—$17,848,444

Current Active Organization and Grant Number

The purpose of this study is to establish virtual research hubs that focus on progenitor cell biology. Investigators are seeking to identify and characterize progenitor cell lineages, direct differentiation of stem and progenitor cells to desired cell fates, and develop new strategies to address the unique challenges presented by the transplantation of progenitor cells.

Obligations

Funding History: Fiscal Year 2012—$26,196,688 Fiscal Years 2009–2011—$69,302,980 Total Funding to Date—$95,499,668

The purpose of this study is to translate findings from basic research on human behavior into more effective clinical, community, and population interventions to reduce obesity and improve obesity-related behaviors. Investigators are seeking to develop innovative obesity-reducing strategies that are effective in small-scale trials, acceptable to target populations of interest, and are ready for testing in large-scale randomized clinical and community trials. Some of the projects are expected to have 50–100 percent participation from minority populations.

Obligations

Funding History: Fiscal Year 2012—$4,548,578 Fiscal Years 2009–2011—$15,284,679 Total Funding to Date—$19,833,257

Current Active Organizations and Grant Numbers

Weill Medical College of Cornell University New York, New York —HL-097843

Wayne State University Detroit, Michigan —HL-097889

Rush University Medical Center Chicago, Illinois —HL-097894

University of California, San Francisco San Francisco, California —HL-097973

* Formerly known as Translating Basic Behavioral and Social Sciences Discoveries Into Interventions To Reduce Obesity.

The purpose of this study is to test the safety and efficacy of tadalafil, a pulmonary vasodilator and phosphodiesterase Type 5 (PDE5) inhibitor, in patients with heart failure and reduced left ventricular ejection fraction (LVEF), specifically an LVEF less than 40%, and secondary pulmonary hypertension.

Obligations

Funding History: Fiscal Year 2012—$1,422,791 Total Funding to Date—$1,422,791

Pediatric Heart Network, Initiated in Fiscal Year 2006

Pharmacogenetics Research Network, Initiated in Fiscal Year 2001

The purpose of this program is to establish a network of multidisciplinary, collaborative research groups to study how genetic variation contributes to interindividual differences in responses to medications. Four studies under this initiative are investigating the pharmacogenetics of heart, lung, and blood diseases. One of the projects has 38 percent minority participation. The Pharmacogenetics Knowledgebase (PharmGKB) has been established to integrate information obtained from pharmacogenomics, phenotypes, and genotypes.

Obligations

Funding History: Fiscal Year 2012—$6,498,845 Fiscal Years 2001–2011—$80,953,760 Total Funding to Date—$87,452,605

The purpose of this clinical trial is to determine whether ranolazine will reduce the risk of ventricular arrhythmias and improve survival in high-risk patients who already have an implantable cardiac defibrillator. Currently, very few options are available for treating patients at risk for ventricular arrhythmias—which often leads to death—and ranolazine may be a safe and effective treatment.

Obligations

Funding History: Fiscal Year 2012—$2,287,927 Fiscal Years 2010–2011—$2,279,794 Total Funding to Date—$4,567,721

Current Active Organizations and Grant Numbers

University of Rochester Rochester, New York —HL-096607

University of Rochester Rochester, New York —HL-096610

Reducing the Impact of Hypertension in Low and Middle Income Countries, Initiated in Fiscal Year 2012

The purpose of this study is to support effective interventions that will provide sound scientific evidence for expanding sustainable blood pressure prevention and control programs in low- and middle-income countries at the local, regional, and national levels.

Obligations

Funding History: Fiscal Year 2012—$1,258,006 Total Funding to Date—$1,258,006

The purpose of this study is to determine whether using cardiac computed assisted tomography early in the emergency department triage will enable immediate and safe discharge without further testing of a significant number of patients with acute chest pain.

Obligations

Funding History: Fiscal Year 2012—$1,105,318 Fiscal Years 2009–2011—$4,785,713 Total Funding to Date—$5,891,031

The purpose of this program is to determine whether therapeutic hypothermia after pediatric cardiac arrest improves outcomes, including survival, in infants and children. Approximately 50 percent of the patients are expected to come from racial and ethnic minority populations.

Obligations

Funding History: Fiscal Year 2012—$4,370,676 Fiscal Years 2009–2011—$10,395,495 Total Funding to Date—$14,766,171

Current Active Organizations and Grant Numbers

University of Utah Salt Lake City, Utah —HL-094339

University of Michigan Ann Arbor, Michigan —HL-094345

Lung Diseases Program

Asthma Networks (AsthmaNet), Initiated in Fiscal Year 2009

Genomic Research in ATT-Deficiency and Sarcoidosis Study (GRADS), Initiated in Fiscal Year 2012

The purposes of this study are to identify molecular abnormalities in patients with alpha-1-antitrypsin deficiency (ATT) or sarcoidosis through genomic and microbiomic analyses and to determine the relationship of these abnormalities to the clinical characteristics of patients. Clinical studies will be conducted to elucidate pathogenetic mechanisms or to identify predictors of disease development and progression. Many of the projects will have at least 50-percent participation from minority populations.

Obligations

Funding History: Fiscal Year 2012—$3,204,534 Total Funding to Date—$3,204,534

Current Active Organizations and Grant Numbers

Vanderbilt University Nashville, Tennessee —HL-112694

National Jewish Health Denver, Colorado —HL-112695

University of California, San Francisco San Francisco, California —HL-112696

Yale University New Haven, Connecticut —HL-112702

University of Pittsburgh at Pittsburgh Pittsburgh, Pennsylvania —HL-112707

Johns Hopkins University Baltimore, Maryland —HL-112708

University of Pittsburgh at Pittsburgh Pittsburgh, Pennsylvania —HL-112711

The purpose of this study is to determine whether safe and effective tight glycemic control can sufficiently reduce morbidity and mortality in children with heart and lung failure to justify a low risk of hypoglycemia.

Obligations

Funding History: Fiscal Year 2012—$2,548,137 Fiscal Year 2011—$2,685,460 Total Funding to Date—$5,233,597

Current Active Organizations and Grant Numbers

Children's Hospital Boston Boston, Massachusetts —HL-107681

Children's Hospital Boston Boston, Massachusetts —HL-108028

Lung Repair and Regeneration Consortium, Initiated in Fiscal Year 2012

The purpose of this consortium is to establish multidisciplinary teams of investigators, cutting edge technologies, innovative strategies, and new ideas to investigate novel hypotheses that are relevant to lung repair and regeneration in order to move the field of lung regeneration forward toward the development of new therapies for human diseases.

Obligations

Funding History: Fiscal Year 2012—$4,910,973 Total Funding to Date—$4,910,973

Current Active Organizations and Grant Numbers

University of Pennsylvania Philadelphia, Pennsylvania —HL-110942

Children's Hospital Center Cincinnati Cincinnati, Ohio —HL-110964

Duke University Durham, North Carolina —HL-110967

Yale University New Haven, Connecticut —HL-111016

Duke University Durham, North Carolina —HL-111018

University of California, San Francisco San Francisco, California —HL-111054

Microbiome of the Lung and Respiratory Tract in HIV-Infected Individuals and HIV-Uninfected Controls, Initiated in Fiscal Year 2009

The purpose of this study is to characterize the microbiome of the lung alone or in combination with the upper airways in HIV-infected individuals and matched HIV-uninfected controls. Investigators are using molecular techniques to identify bacteria, and if possible, other organisms (e.g. , viruses, cell-wall deficient organisms, protozoa, and fungi). Data will be used to examine the effects of changes in the respiratory microbiome on the pathogenesis and progression of HIV disease, HIV-related respiratory complications, and anti-HIV therapies.

Obligations

Funding History: Fiscal Year 2012—$5,289,811 Fiscal Years 2009–2011—$16,067,661 Total Funding to Date—$21,357,472

Pharmacogenetics of Asthma Treatment, Initiated in Fiscal Year 2000

The objective of this project is to bring together research experts in asthma, epidemiology, statistics, bioinformatics, physiology, clinical trials, genetics, and genomics to focus on the pharmacogenetics of asthma treatment.

Obligations

Funding History: Fiscal Year 2012—$1,958,575 Fiscal Years 2000–2011—$30,955,719 Total Funding to Date—$32,914,294

Current Active Organization and Grant Number

Brigham and Women's Hospital Boston, Massachusetts —HL-065899

Prematurity and Respiratory Outcomes Program (PROP), Initiated in Fiscal Year 2010

The purpose of this observational clinical study is to investigate hypotheses on the molecular mechanisms that contribute to respiratory disease risk of the premature newborn with the long-term goal of improving outcomes in the first year of life.

Obligations

Funding History: Fiscal Year 2012—$4,119,773 Fiscal Years 2010–2011—$5,664,228 Total Funding to Date—$9,784,001

Current Active Organizations and Grant Numbers

Vanderbilt University Nashville, Tennessee —HL-101456

Washington University St. Louis, Missouri —HL-101465

University of Pennsylvania Philadelphia, Pennsylvania —HL-101794

University of California, San Francisco San Francisco, California —HL-101798

Preterm Birth in Nulliparous Women: An Understudied Population at Great Risk, Initiated in Fiscal Year 2010

The purpose of this study is to create a network of clinical research sites with a Data Coordinating and Analysis Center to develop common research protocols to study the cardiovascular health of women in their first pregnancy and assess the significance of disordered breathing.

Obligations

Funding History: Fiscal Year 2012—$668,815 Fiscal Years 2010–2011—$3,798,000 Total Funding to Date—$4,466,815

Current Active Organization and Grant Number

Research Triangle Institute Research Triangle, North Carolina —HD-063069

Randomized Trial of Antenatal Late Preterm Steroids (ALPS), Initiated in Fiscal Year 2010

The purpose of this study is to determine whether antenatal corticosteroids can potentially improve lung function and reduce respiratory morbidity in newborn infants who are born in the late preterm period (34–36 weeks). Previous studies have shown that steroids improve lung function in very premature infants. Fifty-five percent of the participants are expected to come from racial and ethnic minority populations.

Obligations

Funding History: Fiscal Year 2012—$556,659 Fiscal Years 2010–2011—$4,271,361 Total Funding to Date—$4,828,020

The purpose of this randomized clinical trial is to determine whether supplemental vitamin D to increase the level of vitamin D in a pregnant woman will prevent asthma and allergy in her child at age 3 years. Investigators will recruit 870 pregnant women who are in the first trimester of pregnancy and randomize them to one of two treatment arms of a 4-year clinical trial: one arm being treatment with 4,000 international units of vitamin D in addition to typical prenatal vitamins and the other being treatment with typical prenatal vitamins alone. Currently, 80 percent of the participants are from racial and ethnic minority populations.

Obligations

Funding History: Fiscal Year 2012—$2,505,636 Fiscal Years 2009–2011—$7,445,255 Total Funding to Date—$9,950,891

The purpose of this randomized clinical trial is to test an innovative approach to sedation management that includes team education and consensus on the use of sedatives in pediatric patients supported on mechanical ventilation; team identification of each patient's trajectory of illness and daily prescription of a sedation goal; use of a nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines; and team feedback on sedation management performance. Investigators have randomized 2,754 critically ill infants and children into two study groups: sedation management intervention and usual care. Forty-five percent of the patients are from racial and ethnic minority populations.

Obligations

Funding History: Fiscal Year 2012—$384,556 Fiscal Years 2008–2011—$9,960,315 Total Funding to Date—$10,344,871

Current Active Organization and Grant Number

Children's Hospital Boston Boston, Massachusetts —HL-086649

Severe Asthma Research Program,* Initiated in Fiscal Year 2011

The purpose of this study is to define severe asthma at the molecular and cellular levels longitudinally to understand its evolution. Research findings will serve as a rational basis for designing mechanism-based diagnostic, prognostic, and treatment strategies for severe asthma.

Obligations

Funding History: Fiscal Year 2012—$6,066,314 Fiscal Year 2011—$5,159,933 Total Funding to Date—$11,226,247

* The Severe Asthma Research Program began in FY 2001 and was funded under the R01 mechanism.

Study of Asthma and Nasal Steroids (STAN), Initiated in Fiscal Year 2009

The purpose of this clinical trial is to determine whether treatment of chronic rhinitis and sinusitis with a nasal steroid improves asthma control. Investigators have randomized 380 patients with poorly controlled asthma and chronic rhinitis and sinusitis to a nasal steroid or matching placebo in addition to their regular asthma treatment. One third of participants are expected to be from minority populations.

Obligations

Funding History: Fiscal Year 2012—$724,801 Fiscal Years 2009–2011—$2,174,420 Total Funding to Date—$2,899,221

Current Active Organizations and Grant Numbers

University of Vermont Burlington, Vermont —HL-089464

Johns Hopkins University Baltimore, Maryland —HL-089510

Study of Soy Isoflavones in Asthma (SOYA), Initiated in Fiscal Year 2009

The purpose of this double-blind, randomized con­trolled trial is to determine whether genistein supplements (soy isoflavone) improves lung func­tion in patients with poorly controlled asthma. The study includes 380 patients with low dietary soy intake, ages 12 years and older, who are taking either inhaled corticosteroids or leukotriene modifiers or both and have poorly controlled asthma. Participants are being randomly assigned to treatment with either a soy isoflavone supplement (containing genistein, daidzein, and glycitein) 100 mg daily or to placebo for 6 months. Thirty percent of participants are expected to be from minority populations.

Obligations

Funding History: Fiscal Year 2012—$687,123 Fiscal Years 2009–2011—$2,106,527 Total Funding to Date—$2,793,650

Current Active Organizations and Grant Numbers

Northwestern University Evanston, Illinois —HL-087987

Johns Hopkins University Baltimore, Maryland —HL-088367

Trial of Late Surfactant (TOLSURF) To Prevent Bronchopulmonary Dysplasia, Initiated in Fiscal Year 2009

The purpose of this randomized controlled clinical trial is to determine whether late doses of surfactant in addition to iNO administered to extremely low gestational age neonates (< 30 weeks) who require mechanical ventilation between 7 and 14 days of age will increase survival without bronchopulmonary dysplasia.

Obligations

Funding History: Fiscal Year 2012—$1,653,180 Fiscal Years 2009–2011—$5,572,999 Total Funding to Date—$7,226,179

Current Active Organizations and Grant Numbers

University of California, San Francisco San Francisco, California —HL-094338

University of California, San Francisco San Francisco, California —HL-094355

The purpose of this study is to determine the safety and efficacy of low molecular weight heparin (LMWH) in adults with atrial fibrillation who stop warfarin in preparation for surgery. The trial randomly allocated 3,282 patients with atrial fibrillation to either LMWH or placebo before and after surgery. Investigators hypothesize that simply withholding warfarin in a perioperative setting for patients with atrial fibrillation will not meaningfully increase the risk for arterial thromboembolism and will forestall hemorrhagic complications, compared with a strategy using LMWH before and after surgery. One-third of participants are expected to be from minority populations.

Obligations

Funding History: Fiscal Year 2012—$0 Fiscal Years 2008–2011—$15,531,903 Total Funding to Date—$15,531,903

Current Active Organizations and Grant Numbers

The purpose of this study is to determine whether higher hemoglobin thresholds for transfusing extremely low birth weight babies born at less than 1,000 grams increases survival and improves long-term neurodevelopment at 18–22 months of age. The TABI trial is partnering with the NICHD Neonatal Research network and its 18 clinical centers.

Obligations

Funding History: Fiscal Year 2012—$1,729,189 Total Funding to Date—$1,729,189

Current Active Organizations and Grant Numbers

Research Triangle Institute Research Triangle, North Carolina —HL-112748

Transfusion Medicine/Hemostasis Clinical Research Network, Initiated in Fiscal Year 2002

NHLBI Centers of Research Program (P50)

The Centers of Research Program supports specialized centers that focus on multidisciplinary research and development from basic science to clinical investigation in response to announcements of the programmatic needs of the Institute. The spectrum of activities comprises a multifaceted attack on a specific disease entity or biomedical problem area.

NHLBI Centers of Research Program

Obligations (Dollars in Thousands)

Type of Center

Period of Operation

Prior to FY 2012

FY 2012

Total to Date

NIH Centers for Population Health and Health Disparities (CPHHD)

2010–

$20,067

$6,711

$26,778

Subtotal, CPHHD

20,067

6,711

26,778

Specialized Centers of Clinically Oriented Research (P50)

Heart and Vascular Diseases Program

Vascular Injury, Repair, and Remodeling (SCCOR)

2006–

71,403

2,831

74,234

Subtotal, Heart and Vascular Diseases Program

71,403

2,831

74,234

Lung Diseases Program

Chronic Obstructive Pulmonary Disease (SCCOR)

2007–

53,556

2,578

56,134

Pulmonary Vascular Disease (SCCOR)

2007–

30,218

1,516

31,734

Subtotal, Lung Diseases Program

83,774

4,094

87,868

Subtotal, SCCORs (P50)

155,177

6,925

162,102

Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases (CADET) Phase I

2011–

9,001

8,850

17,851

Subtotal, CADET Phase I

9,001

8,850

17,851

NHLBI Translational Research Implementation Program (TRIP)

2012–

—

11,676

11,676

Subtotal, TRIP

—

11,676

11,676

Total, Centers of Research Program (P50)

$184,245

$34,162

$218,407

NIH Centers for Population Health and Health Disparities (CPHHD) (P50)

The purpose of this program is to create centers of transdisciplinary research that will evaluate the multilevel determinants of health disparities and devise interventions to reduce them.

Obligations

Fiscal Year 2012 $6,711,003

Current Active Organizations and Grant Numbers

University of North Carolina, Chapel Hill Chapel Hill, North Carolina HL-105184

Specialized Centers of Clinically Oriented Research (P50)

The NHLBI initiated the Specialized Centers of Research (SCOR) program in 1971 to encourage translational research converting basic science findings to the clinic in high priority areas. The SCOR concept emphasized multidisciplinary research (i.e., basic science and clinical investigations) on diseases relevant to the Institute's mission. In FY 2002, the NHLBI revised its SCOR program primarily on recommendation from the NHLBAC to place more emphasis on clinical research projects. The SCCOR program still requires clinical and basic scientists to work together on a unified theme, but also requires at least 50 percent of the projects to be clinical. The SCOR program ended in FY 2008.

A description of the SCCORs supported by the Institute follows.

Heart Diseases Program

Vascular Injury, Repair, and Remodeling

The purpose of this SCCOR is to stimulate interdependent clinical and multidisciplinary basic research projects that investigate molecular and cellular mechanisms of vascular injury, repair, and remodeling; promote patient-oriented research that will improve our ability to prevent, detect, characterize, manage, and treat vascular diseases; and develop the skills and research capabilities of new clinical investigators.

Obligations

Fiscal Year 2012 $2,830,751

Current Active Organization and Grant Number

Beth Israel Deaconess Medical Center Boston, Massachusetts HL-083813

Lung Diseases Program

Chronic Obstructive Pulmonary Disease

The purpose of this SCCOR is to foster multidisciplinary research to accelerate progress in the diagnosis, prevention, and treatment of COPD.

Obligations

Fiscal Year 2012 $2,578,270

Current Active Organization and Grant Number

University of Pittsburgh Pittsburgh, Pennsylvania HL-084948

Pulmonary Vascular Disease

The objective of this SCCOR is to facilitate multidisciplinary research that proposes original hypotheses and applies cutting-edge approaches, including genomics and proteomics, to clinical issues in pulmonary vascular disease.

Obligations

Fiscal Year 2012 $1,515,534

Current Active Organization and Grant Number

The purpose of this program is to accelerate the development of novel agents for the diagnosis and treatment of lung diseases and sleep disordered breathing through the use of rational strategies based on fundamental pathobiologic processes. CADET I provides opportunities to explore potential targets for validation to determine which are amenable for development of mechanism-based modalities for direct clinical application in the prevention, diagnosis, and treatment of pulmonary diseases and sleep disordered breathing.

University of North Carolina, Chapel Hill Chapel Hill, North Carolina HL-107168

Johns Hopkins University Baltimore, Maryland HL-107169

University of Chicago Chicago, Illinois HL-107171

University of Pittsburgh Pittsburgh, Pennsylvania HL-107172

University of Michigan Ann Arbor, Michigan HL-107177

Duke University Durham, North Carolina HL-107180

University of Alabama, Birmingham Birmingham, Alabama HL-107181

Johns Hopkins University Baltimore, Maryland HL-107182

Washington University Saint Louis, Missouri HL-107183

Johns Hopkins University Baltimore, Maryland HL-107185

University of Texas Health Center at Tyler Tyler, Texas HL-107186

University of Arizona Tucson, Arizona HL-107188

Johns Hopkins University Baltimore, Maryland HL-107190

University of California, San Francisco San Francisco, California HL-107191

Brigham and Women's Hospital Boston, Massachusetts HL-107192

NHLBI Translational Research Implementation Program (C-TRIP) (P50)

The C-TRIP program was initiated in FY 2010 to accelerate the translation of promising new therapeutic interventions derived from fundamental research discoveries for the treatment and prevention of heart failure or arrhythmias. The program consists of two stages. Stage 1 focused on planning and developing clinical trials to determine the safety and efficacy of interventions to be conducted during Stage 2 of the overall program. Stage 2 TRIP studies are supported by the P50 mechanism.

Obligation

Fiscal Year 2012 $11,676,397

Current Active Organizations and Grant Numbers

Fred Hutchinson Cancer Research Center Seattle, Washington HL-110787

Tufts Medical Center Boston, Massachusetts HL-110789

Dana-Farber Cancer Institute Boston, Massachusetts HL-110790

Mount Sinai School of Medicine New York, New York HL-112324

Brigham and Women's Hospital Boston, Massachusetts HL-112349

Translational Research Centers in Thrombotic and Hemostatic Disorders (TRC-THD) (U54)

The purpose of this program is to enhance the translation of basic research discoveries that have the potential to improve the prevention, diagnosis, and treatment of thrombotic and hemostatic disorders. Investigators will advance early stage translational research, integrating applied and basic science, to move research discoveries toward clinical application.

Obligations

Fiscal Year 2012 $11,442,192

Current Active Organizations and Grant Numbers

Beth Israel Deaconess Medical Center Boston, Massachusetts HL112302

Washington University St. Louis, Missouri HL112303

Duke University Durham, North Carolina HL112307

Emory University Atlanta, Georgia HL112309

University of Utah Salt Lake City, Utah HL112311

Centers for AIDS Research (P30) Program

The NHLBI, along with five other NIH Institutes, contributes to the support of six Centers for AIDS Research that were established to provide a multidisciplinary environment that promotes basic, clinical, behavioral, and translational research activities in the prevention, detection, and treatment of HIV infection and AIDS. Almost half of the patient population comes from minority groups.

Obligations

Fiscal Year 2012 $3,428,458

Current Active Organizations and Grant Numbers

University of Washington Seattle, Washington AI-027757

University of California, San Francisco San Francisco, California AI-027763

University of North Carolina, Chapel Hill Chapel Hill, North Carolina AI-050410

Yeshiva University New York, New York AI-051519

Vanderbilt University Nashville, Tennessee AI-054999

Harvard Medical School Boston, Massachusetts AI-060354

Duke University Durham, North Carolina AI-064518

University of Miami School of Medicine Coral Gables, Florida AI-073961

University of Rochester Rochester, New York AI-078498

Rush University Medical Center Chicago, Illinois AI-082151

George Washington University Washington, DC AI-087714

Anchoring Metabolomic Changes to Phenotype Program (P20)

The purpose of this program is to gain mechanistic understanding of the molecular determinants that contribute to cardiovascular and lung disease phenotypes through metabolomic phenotyping of existing cohorts to help in predicting disease susceptibility, diagnosis, and risk stratification; assessing response to therapy; and assessing prognosis. The program will consist of two interacting components, a metabolomic component and a mechanistic component, each informing the other in an iterative manner.

Obligations

Fiscal Year 2012 $2,899,225

Current Active Organizations and Grant Numbers

Weill Medical College of Cornell University New York, New York HL-113443